Poulton Stuart

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
6
Insider Sells Sum
$60,862.34

Insider Activity of Poulton Stuart

According to the SEC Form 4 filings, Poulton Stuart, being in a position of

  1. EVP, Chief Development Officer at Karyopharm Therapeutics Inc.,
    оver the last 12 months, has bought 0 shares, and sold 31196 shares for $37,309,
    over all time since 2023-02-15, has bought 0 shares, and sold 39910 shares for $60,862.

The largest sale of all time was on 2024-02-29 and amounted to 16311 share of Karyopharm Therapeutics Inc. for $19,084.

Biography of Poulton Stuart

No biography is available at this moment.

2024-07-30SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
2,883
0.0023%
$1.06$3,056-12.86%
2024-03-01SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
6,155
0.0055%
$1.20$7,386-14.29%
2024-02-29SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
16,311
0.0149%
$1.17$19,084-12.07%
2024-02-15SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
5,847
0.005%
$1.33$7,783-18.85%
2023-07-28SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
2,845
0.0026%
$1.70$4,837-37.78%
2023-02-15SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Development Officer
5,869
0.0045%
$3.19$18,717-57.79%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.